The Future of EU HTA: How Pharmaceutical Companies Can Prepare for the New Process

Whitepaper Clinical Studies Pharmaceutical Research and Development

thumbnail of content

Gain a deeper understanding of:

EU HTA and what it means for you
HTA at the EU level
Common stakeholder concerns: complexity, timeframe, lack of stakeholder involvement and disconnection in processes
Intended effects vs. the reality
How to get ready for 2025
Questions about the future of EU HTA

Download the Whitepaper

Your company email address

Please select your industry: (max 1)
I would like to hear more from an IQVIA expert

Opt In?

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow IQVIA to store and process the information submitted to provide you the content requested. They are subject to IQVIA Terms and Conditions.

Explore similar content

thumbnail of the content

Resiliency and innovation - Navigating the current biotech landscape

Gain insight from ICON’s Biotech President, Chris Smyth, on the biggest barriers to success in biotech, and the key strategies required to survive and thrive in this dynamic and competitive landscape. Download the article to gain perspective on the:

Article Clinical Studies Pharmaceutical Research and Development

thumbnail of the content

HIV – Global Clinical Trial Landscape

Explore the far-reaching impact of HIV, the latest global research priorities, and the innovative treatments, such as Antiretroviral therapy (ART), that offer hope in finding a cure. Gain insights from CRO experts, Novotech, on key topics, such as:

Report Clinical Studies Pharmaceutical Research and Development

thumbnail of the content

Incorporating Digital Biomarkers & Endpoints Into Clinical Trials: Key Regulatory Considerations

As technology advances and innovations like digital endpoints and biomarkers become more prevalent, regulatory considerations surrounding them become more complex. Navigate this evolving space, with insights from this free webinar. Experts from Biofourmis will share their insights into:

Webinar Clinical Studies Pharmaceutical Research and Development